Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
LETTERS TO THE EDITOR

Cure of Listeria monocytogenes Meningitis after Early Transition to Oral Therapy

Matthew H. Grant, Hannah Ravreby, Bennett Lorber
Matthew H. Grant
Temple University School of Medicine and Hospital Philadelphia, Pennsylvania 19140
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hannah Ravreby
Temple University School of Medicine and Hospital Philadelphia, Pennsylvania 19140
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bennett Lorber
Temple University School of Medicine and Hospital Philadelphia, Pennsylvania 19140
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bennett.lorber@temple.edu
DOI: 10.1128/AAC.01815-09
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Due to its lethality, Listeria monocytogenes infection of the central nervous system (CNS) typically is treated parenterally. We describe a case of L. monocytogenes meningitis cured with trimethoprim-sulfamethoxazole (TMP-SMX) utilizing early oral therapy on an outpatient basis.

A 64-year-old woman was hospitalized with an acute onset of fever and personality change. She had a history of hypertension and rheumatoid arthritis controlled with weekly methotrexate without recent exposure to corticosteroids or tumor necrosis factor-alpha antagonists. Ten days before the current illness, she experienced a 3-day, self-limited episode of fever, vomiting, and diarrhea. The day of admission, her family noted the abrupt onset of bizarre behavior. She began attempting to rearrange furniture and shouting obscenities, which progressed into incoherent speech. After witnessing a fall without head strike, her family brought her to the hospital.

At the time of admission, she was confused. Her temperature was 39.3°C. She had nuchal rigidity and photophobia without focal neurological findings. The peripheral leukocyte count was 15,600 cells/mm3 (79% neutrophils, 5% bands, and 14% lymphocytes). A noncontrast computed tomography (CT) examination of the head was unremarkable. Cerebrospinal fluid (CSF) contained 545 leukocytes/mm3 (77% neutrophils), a protein level of 209 mg/dl, and a glucose level of 62 mg/dl (serum glucose, 128 mg/dl). Gram stain showed few leukocytes but no organisms.

After obtaining a history of oro-labial swelling following penicillin, the patient was given intravenous vancomycin, moxifloxacin, and TMP-SMX (15 mg/kg of body weight TMP daily in four divided doses). Dexamethasone and acyclovir were also administered for the first 48 h. After L. monocytogenes was isolated from the CSF, treatment was continued with TMP-SMX alone. Within 4 days she was afebrile, alert, and oriented and no longer had nuchal rigidity. In face of the rapid clinical response and with the availability of reliable family members to ensure adherence, the patient was discharged on hospital day 5 on oral TMP-SMX (three single-strength tablets every 6 h) to complete 3 weeks of treatment. She was completely well at an office visit 1 week after completing therapy and by phone interview 6 weeks after completion.

No controlled trials exist to establish a drug of choice, mode of delivery, or optimal duration of therapy for CNS listeriosis. Ampicillin is the preferred and most widely used agent; many authorities recommend the addition of an aminoglycoside to ampicillin for at least the first week in treatment of CNS infection (4). For patients with penicillin hypersensitivity, TMP-SMX is the treatment of choice.

Comparable levels of TMP-SMX are attained in the CSF with oral and intravenous administration (1). There have been several reported cases of L. monocytogenes meningitis treated successfully with oral TMP-SMX or TMP alone (Table 1). Together with this report, they suggest that oral TMP-SMX can be an efficacious and inexpensive therapeutic option for patients who demonstrate rapid clinical response to intravenous therapy and in whom good adherence is expected.

View this table:
  • View inline
  • View popup
TABLE 1.

Cases of L. monocytogenes meningitis treated with oral TMP-SMX

ACKNOWLEDGMENTS

There are no potential conflicts of interest for any of the authors of this report.

  • Copyright © 2010 American Society for Microbiology

REFERENCES

  1. 1.↵
    Gunther, G., and A. Philipson. 1988. Oral trimethoprim as follow-up treatment of meningitis caused by Listeria monocytogenes. Rev. Infect. Dis.10:53-55.
    OpenUrlPubMed
  2. 2.
    Jacquette, G., and P. H. Dennehy. 1985. Trimethoprim-sulfamethoxazole in Listeria monocytogenes meningitis. Ann. Intern. Med.102:866-867.
    OpenUrlPubMed
  3. 3.
    Kaufmann, S., and R. Hennes. 1973. Klinische erfahrungen und pharmako-kinetische untersuchungen mit bactrim “roche” bei meningitis. Med. Welt.24:1903-1906.
    OpenUrlPubMed
  4. 4.↵
    Lorber, B. 2010. Listeria monocytogenes, p. 2707-2714. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 7th ed., vol 2. Elsevier-Churchill Livingstone, Philadelphia, PA.
  5. 5.
    Scheer, M. S., and S. Z. Hirschman. 1982. Oral and ambulatory therapy of Listeria bacteremia and meningitis with trimethoprim-sulfamethoxazole. Mt. Sinai J. Med.49:411-414.
    OpenUrlPubMed
PreviousNext
Back to top
Download PDF
Citation Tools
Cure of Listeria monocytogenes Meningitis after Early Transition to Oral Therapy
Matthew H. Grant, Hannah Ravreby, Bennett Lorber
Antimicrobial Agents and Chemotherapy Apr 2010, 54 (5) 2276-2277; DOI: 10.1128/AAC.01815-09

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Cure of Listeria monocytogenes Meningitis after Early Transition to Oral Therapy
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Cure of Listeria monocytogenes Meningitis after Early Transition to Oral Therapy
Matthew H. Grant, Hannah Ravreby, Bennett Lorber
Antimicrobial Agents and Chemotherapy Apr 2010, 54 (5) 2276-2277; DOI: 10.1128/AAC.01815-09
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ACKNOWLEDGMENTS
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

anti-infective agents
Listeria monocytogenes
Meningitis, Listeria
Trimethoprim, Sulfamethoxazole Drug Combination

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596